Bayer Plunges on Drug Setback, $1.5 Billion Roundup Verdict
Bayer AG faces two fresh setbacks, causing the stock to plummet, after stopping the main study of its
2023-11-20 16:52
Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep
Problems at a Catalent Inc. production facility led US regulators to deny a key drug application from Regeneron
2023-06-29 00:21